ProfileGDS5678 / 1427201_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 79% 84% 66% 75% 71% 68% 74% 71% 70% 71% 69% 63% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7936563
GSM967853U87-EV human glioblastoma xenograft - Control 25.4932479
GSM967854U87-EV human glioblastoma xenograft - Control 36.2201684
GSM967855U87-EV human glioblastoma xenograft - Control 44.0483166
GSM967856U87-EV human glioblastoma xenograft - Control 55.0393975
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4618171
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1940968
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8724474
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4409871
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.4118370
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4421271
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3089169
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7910763
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4466671